✦ LIBER ✦

Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy

✍ Scribed by Teh-Ia Huo; Yi-Hsiang Huang; Chien-Wei Su; Han-Chieh Lin; Jen-Huei Chiang; Yi-You Chiou; Samantha C. Huo; Pui-Ching Lee; Shou-Dong Lee

Book ID: 110889955
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 165 KB
Volume: 22
Category: Article
ISSN: 0902-0063
DOI: 10.1111/j.1399-0012.2008.00811.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Determination of the optimal model for e

Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy

✍ Teh-Ia Huo; Jaw-Ching Wu; Han-Chieh Lin; Fa-Yauh Lee; Ming-Chih Hou; Yi-Hsiang H 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

The model for end-stage liver disease (MELD) has been a prevailing system to prioritize cirrhotic patients awaiting liver transplantation. An "exceptional" MELD score of 20 and 24 points is assigned for stage T1 and T2 patients with small hepatocellular carcinoma (HCC), respectively. However, this s

Abstract No. 241: Worldwide trends in lo

Abstract No. 241: Worldwide trends in locoregional therapy for hepatocellular carcinoma (HCC): First interim analysis of the global investigation of therapeutic decisions in HCC and of its treatment with sorafenib (GIDEON) study

✍ Geschwind, J.F.; Lencioni, R.; Marrero, J.; Venook, A.; Ye, S.; Nakajima, K.; Ku 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 83 KB

1392 POSTER Tolerance and efficacy of hi

1392 POSTER Tolerance and efficacy of high-dose 3D-Conformal Radiation Therapy (CRT) in cirrhotic patients with small hepatocellular carcinomas (HCC) not suitable for curative therapies

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Abstract No. 196: Worldwide trends in lo

Abstract No. 196: Worldwide trends in locoregional therapy (LRT) for hepatocellular carcinoma (HCC): 2nd interim analysis (IA; 1500 patients [pts]) of the GIDEON (global investigation of therapeutic decisions in HCC and of its treatment with sorafenib) study

✍ Geschwind, J.F.; Lencioni, R.; Marrero, J.; Venook, A.; Ye, S.; Nakajima, K.; Ku 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 55 KB

786 DEVELOPMENT AND VALIDATION OF THE NA

786 DEVELOPMENT AND VALIDATION OF THE NAPOLI PROGNOSTIC INDEX (NAPI): A NEW RISK SCORE FOR PREDICTING DEATH IN CIRRHOTIC PATIENTS WITH TREATABLE HEPATOCELLULAR CARCINOMA (HCC)

✍ G.G. Di Costanzo; P. Pagliano; M. De Luca; L. Addario; C. Pacella; M.T. Tartagli 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB